DDInter150 DDInter927
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Azathioprine {u} (Compound) resembles {v} (Compound) Adenine
Azathioprine {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
Azathioprine {u} (Compound) binds {v} (Gene) GSTA1
Azathioprine {u} (Compound) upregulates {v} (Gene) NUCB2
Azathioprine {u} (Compound) is included by {v} (Pharmacologic Class) Purines
Azathioprine {u} (Compound) downregulates {v} (Gene) STUB1
Azathioprine {u} (Compound) causes {v} (Side Effect) Hodgkin's disease
Azathioprine (Compound) resembles Adenine (Compound)
Azathioprine (Compound) treats systemic lupus erythematosus (Disease)
Azathioprine (Compound) binds GSTA1 (Gene)
Azathioprine (Compound) upregulates NUCB2 (Gene)
Azathioprine (Compound) is included by Purines (Pharmacologic Class)
Azathioprine (Compound) downregulates STUB1 (Gene)
Azathioprine (Compound) causes Hodgkin's disease (Side Effect)